Tags

Type your tag names separated by a space and hit enter

Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.
Pain Pract. 2009 Sep-Oct; 9(5):363-74.PP

Abstract

OBJECTIVE

To characterize comorbidities, pain-related pharmacotherapy, and healthcare resource use among patients with fibromyalgia (FM) newly prescribed pregabalin or gabapentin in clinical practice.

METHODS AND DESIGN

Using the PharMetrics Database, FM patients (International Classification of Diseases, Ninth Revision, Clinical Modification code 729.1X) newly prescribed pregabalin (n = 1,606; mean age 49.9 +/- 9.6 years; 87.9% female) and gabapentin (n = 930; mean age 49.5 +/- 9.6 years; 86.6% female) on/after July 1, 2007 were identified. Prevalence of comorbidities, pharmacotherapy, and healthcare resource use/costs (pharmacy, outpatient, inpatient, total) were examined during the 6 months preceding (preindex) and following (postindex) the date of their first pregabalin or gabapentin (index) prescription.

RESULTS

Patients in both cohorts had a variety of comorbidities and used multiple medications. There were significant decreases (P values < 0.05) in the use of nonsteroidal anti-inflammatory drugs (32.1% vs. 29.5%), anticonvulsants (27.0% vs. 22.0%), and combination therapies in the pregabalin cohort in the postindex period. There were significant increases (all P values < 0.05) in use of short-acting opioids (58.8% vs. 63.7%), any opioids (61.5% vs. 65.6%), serotonin-norepinephrine reuptake inhibitors (22.5% vs. 24.5%), anticonvulsants (16.3% vs. 26.2%), benzodiazepines (33.2% vs. 36.6%), topical agents (6.6% vs. 9.0%), and combination therapies in the gabapentin cohort. Although there were no changes in units of healthcare resources used, there were increases in the postindex period in hospitalization, medications, and total costs for pregabalin, and office visits and medication costs for gabapentin (all P values < 0.05).

CONCLUSIONS

Results suggest a high comorbidity and medication use burden in FM patients in this study. Further evaluation is warranted to clarify differences in resource utilization/costs observed with these two anticonvulsants.

Authors+Show Affiliations

Avalon Health Solutions, Inc., Philadelphia, Pennsylvania 19103, USA. mgore@avalonhealthsolutions.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19500273

Citation

Gore, Mugdha, et al. "Clinical Characteristics, Pharmacotherapy and Healthcare Resource Use Among Patients With Fibromyalgia Newly Prescribed Gabapentin or Pregabalin." Pain Practice : the Official Journal of World Institute of Pain, vol. 9, no. 5, 2009, pp. 363-74.
Gore M, Sadosky AB, Zlateva G, et al. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009;9(5):363-74.
Gore, M., Sadosky, A. B., Zlateva, G., & Clauw, D. J. (2009). Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Practice : the Official Journal of World Institute of Pain, 9(5), 363-74. https://doi.org/10.1111/j.1533-2500.2009.00292.x
Gore M, et al. Clinical Characteristics, Pharmacotherapy and Healthcare Resource Use Among Patients With Fibromyalgia Newly Prescribed Gabapentin or Pregabalin. Pain Pract. 2009 Sep-Oct;9(5):363-74. PubMed PMID: 19500273.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. AU - Gore,Mugdha, AU - Sadosky,Alesia Beth, AU - Zlateva,Gergana, AU - Clauw,Daniel J, Y1 - 2009/06/04/ PY - 2009/6/9/entrez PY - 2009/6/9/pubmed PY - 2009/12/16/medline SP - 363 EP - 74 JF - Pain practice : the official journal of World Institute of Pain JO - Pain Pract VL - 9 IS - 5 N2 - OBJECTIVE: To characterize comorbidities, pain-related pharmacotherapy, and healthcare resource use among patients with fibromyalgia (FM) newly prescribed pregabalin or gabapentin in clinical practice. METHODS AND DESIGN: Using the PharMetrics Database, FM patients (International Classification of Diseases, Ninth Revision, Clinical Modification code 729.1X) newly prescribed pregabalin (n = 1,606; mean age 49.9 +/- 9.6 years; 87.9% female) and gabapentin (n = 930; mean age 49.5 +/- 9.6 years; 86.6% female) on/after July 1, 2007 were identified. Prevalence of comorbidities, pharmacotherapy, and healthcare resource use/costs (pharmacy, outpatient, inpatient, total) were examined during the 6 months preceding (preindex) and following (postindex) the date of their first pregabalin or gabapentin (index) prescription. RESULTS: Patients in both cohorts had a variety of comorbidities and used multiple medications. There were significant decreases (P values < 0.05) in the use of nonsteroidal anti-inflammatory drugs (32.1% vs. 29.5%), anticonvulsants (27.0% vs. 22.0%), and combination therapies in the pregabalin cohort in the postindex period. There were significant increases (all P values < 0.05) in use of short-acting opioids (58.8% vs. 63.7%), any opioids (61.5% vs. 65.6%), serotonin-norepinephrine reuptake inhibitors (22.5% vs. 24.5%), anticonvulsants (16.3% vs. 26.2%), benzodiazepines (33.2% vs. 36.6%), topical agents (6.6% vs. 9.0%), and combination therapies in the gabapentin cohort. Although there were no changes in units of healthcare resources used, there were increases in the postindex period in hospitalization, medications, and total costs for pregabalin, and office visits and medication costs for gabapentin (all P values < 0.05). CONCLUSIONS: Results suggest a high comorbidity and medication use burden in FM patients in this study. Further evaluation is warranted to clarify differences in resource utilization/costs observed with these two anticonvulsants. SN - 1533-2500 UR - https://www.unboundmedicine.com/medline/citation/19500273/Clinical_characteristics_pharmacotherapy_and_healthcare_resource_use_among_patients_with_fibromyalgia_newly_prescribed_gabapentin_or_pregabalin_ L2 - https://doi.org/10.1111/j.1533-2500.2009.00292.x DB - PRIME DP - Unbound Medicine ER -